In the January article, “SERMs: protection without worry?” Anthony Luciano, MD, states that the National Osteoporosis Foundation (NOF) “recommends hormone replacement therapy (HRT) as the first-line agent for the treatment and prevention of osteoporosis in the general population.”
It is important to note that the FDA has approved HRT for the prevention and management of osteoporosis, but not for treatment. NOF’s recommendations concur with these FDA indications.
Ronald White, Assistant Executive Director
National Osteoporosis Foundation
DR. Luciano responds:
Indeed, the FDA has recently withdrawn its approval of HRT for the treatment of osteoporosis, but it continues to support HRT use for the prevention of osteoporosis. My recommendation is the same until further data suggest otherwise.